tradingkey.logo
tradingkey.logo
검색

Exact Sciences Corp

EXAS
관심 목록에 추가
104.910USD
0.0000.00%
종가 06/29, 16:00ET시세는 15분 지연됩니다
20.03B시가총액
손실P/E TTM

자세한 내용은 Exact Sciences Corp 회사

Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

Exact Sciences Corp 정보

종목 코드 EXAS
회사 이름Exact Sciences Corp
상장일Jan 30, 2001
CEOConroy (Kevin T)
직원 수6900
유형Ordinary Share
회계 연도 종료Jan 30
주소5505 Endeavor Lane
도시MADISON
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호53719
전화16082845700
웹사이트https://www.exactsciences.com/
종목 코드 EXAS
상장일Jan 30, 2001
CEOConroy (Kevin T)

Exact Sciences Corp의 회사 임원진

이름
이름/직위
직위
주식 보유
변동
Mr. Kevin T. Conroy
Mr. Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
279.16K
-457.95%
Mr. Daniel J. (Dan) Levangie
Mr. Daniel J. (Dan) Levangie
Independent Director
Independent Director
34.31K
+15.73%
Ms. Shacey Petrovic
Ms. Shacey Petrovic
Independent Director
Independent Director
7.09K
-307.32%
Mr. Brian Baranick
Mr. Brian Baranick
Executive Vice President, General Manager - Precision Oncology
Executive Vice President, General Manager - Precision Oncology
670.00
-15503.58%
Mr. Aaron Bloomer
Mr. Aaron Bloomer
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
212.00
-23003.77%
Ms. Katherine S. (Kay) Zanotti
Ms. Katherine S. (Kay) Zanotti
Independent Director
Independent Director
--
-100.00%
Mr. James E. Doyle
Mr. James E. Doyle
Lead Independent Director
Lead Independent Director
--
--
Mr. D. Scott Coward
Mr. D. Scott Coward
Director
Director
--
--
Mr. Jacob (Jake) Orville
Mr. Jacob (Jake) Orville
Executive Vice President, General Manager - Screening
Executive Vice President, General Manager - Screening
--
--
Mr. Paul Clancy
Mr. Paul Clancy
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Kevin T. Conroy
Mr. Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
279.16K
-457.95%
Mr. Daniel J. (Dan) Levangie
Mr. Daniel J. (Dan) Levangie
Independent Director
Independent Director
34.31K
+15.73%
Ms. Shacey Petrovic
Ms. Shacey Petrovic
Independent Director
Independent Director
7.09K
-307.32%
Mr. Brian Baranick
Mr. Brian Baranick
Executive Vice President, General Manager - Precision Oncology
Executive Vice President, General Manager - Precision Oncology
670.00
-15503.58%
Mr. Aaron Bloomer
Mr. Aaron Bloomer
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
212.00
-23003.77%
Ms. Katherine S. (Kay) Zanotti
Ms. Katherine S. (Kay) Zanotti
Independent Director
Independent Director
--
-100.00%

자주 묻는 질문

Exact Sciences Corp의 상위 5대 주주는 누구인가요?

Exact Sciences Corp의 상위 5대 주주는 다음과 같습니다: Mr. Kevin T. Conroy

Exact Sciences Corp(EXAS)의 주식을 보유한 기관은 몇 개입니까?

2026Q1 기준으로, Exact Sciences Corp의 주식을 보유한 기관은 총 1452곳이며, 이들이 보유한 주식의 총 가치는 약 147.12M로 전체 발행 주식의 77.07%를 차지합니다. 이는 2025Q4 대비 -48700001.00 증가한 수치입니다.

Exact Sciences Corp의 최대 수익원은 무엇인가요?

2026Q1 기준, Exact Sciences Corp의 Commercial 부문이 가장 높은 매출을 기록했으며, 금액은 1.52B로 전체 매출의 46.79%를 차지했습니다.
KeyAI